12 S , 20-Dihydroxyicosatetraenoic acid : A new icosanoid synthesized by neutrophils from 12 S-hydroxyicosatetraenoic acid produced by thrombin-or collagen-stimulated platelets ( aspirin / llpoxygenase / cell-cell interactions / thin-layer and high-performance liquid chromatography / gas chromatogra
A. Marcus,L. Safier,H. Ullman,M. Broekman,N. Islam,Thomas D. OGLESBYt,Robert R. GORMANt
Abstract:A new metabolite of arachidonic acid, formed during interaction between thrombinor collagenstimulated platelets and unstimulated neutrophils, has been demonstrated by both thin-layer radiochromatography and high-performance liquid chromatography. Production of the 3H-labeled metabolite in combined suspensions containing [3H]arachidonate-labeled platelets and unlabeled neutrophils from aspirin-treated donors suggested that platelet 3H-labeled 12S-hydroxy-5,8-cis,10-trans,14-cis-icosatetraenoic acid (12HETE) was the precursor. This was confirmed by identification of the same product when purified 12-[3H]HETE was added directly to unstimulated neutrophils. Hydrogenation and oxidation of the isolated product, followed by gas chromatography-mass spectrometry showed the structure to be 12S,20dihydroxyicosatetraenoic acid. These experiments further show that platelet stimuli known to occur in vivo may initiate metabolic interactions between different cell types via the arachidonic acid pathway. Blood vessel injury with resultant exposure of subendothelial structures such as collagen initiates several hemostatic responses, including platelet aggregation and activation of coagulation, which culminate in thrombin formation (1). Collagen and thrombin also induce release of platelet arachidonic acid and its transformation into icosanoids (1). Cellular components of the hemostatic process such as platelets, neutrophils, and endothelial cells are consequently brought into close apposition-a situation that affords the opportunity for metabolic interchange of biochemical products generated by these cells (2). Using [3H]arachidonate-labeled platelets, we previously showed direct cell-cell interactions between platelets and endothelial cells via the cyclooxygenase pathway in which platelet-derived precursors (endoperoxides) were used by endothelial cells in the formation of prostacyclin (2). More recently, we reported that stimulated radiolabeled platelets interact with stimulated neutrophils via the lipoxygenase pathway of arachidonate metabolism. Thus, released platelet [3H]arachidonate served as precursor for stimulated neutrophil-derived leukotriene B4 (LTB4; SS,12R-dihydroxy-6cis,8,10-trans,14-cis-icosatetraenoic acid) and SS-hydroxy6-trans,8,11,14-cis-icosatetraenoic acid (5-HETE), whereas 3H-labeled 12S-hydroxy-5 ,8-cis,10-trans,14-cis-icosatetraenoic acid (12-HETE) from the platelet served as substrate for SS,12S-dihydroxy-6-trans,8-cis,10-trans,14-cisicosatetraenoic acid (5S,12S-DiHETE) formation (3). The present investigation documents additional platelet-neutrophil interactions involving the lipoxygenase pathway in which a new metabolite of arachidonic acid, 12S,20-dihydroxyicosatetraenoic acid is formed by the unstimulated neutrophil in the presence of thrombinor collagen-stimulated platelets. MATERIALS AND METHODS Preparation of Platelet Suspensions. Blood was collected and processed (2, 4) from donors who had not ingested aspirin or who had taken 650 mg of aspirin 12 and 2 hr prior to venipuncture. Platelets were labeled (2) with 50,uCi (1 Ci = 37 GBq) of [3H]arachidonate added during the first wash (4). Preparation of Neutrophil Suspensions. Suspensions containing 95% neutrophils (5% eosinophils) were prepared from 80-240 ml of whole blood (2) initially centrifuged at 200 x g. After removal of platelet-rich plasma, the remaining leukocytes and erythrocytes were suspended in Dextran T500 (1.5%). Leukocyte-rich plasma was centrifuged at 280 x g (10 min, 40C), and the resulting pellets were suspended in cold saline and layered on Ficoll-Hypaque (density, 1.077). After centrifugation at 350 x g (30 min, 4°C), the interface was removed and erythrocytes in the neutrophil-containing pellet were lysed with distilled water (25 sec). On return to isotonicity with NaCl, phosphate-buffered saline (pH 7.4) was added, the suspension was centrifuged at 280 x g for 5 min (4°C), and the neutrophils were suspended in Hepes buffer containing calcium and magnesium (3). Trypan blue exclusion by the preparation averaged 94%, and on stained smears no platelets were seen. Experimental Procedure. For TLC studies, 3 x 108 labeled platelets were incubated at 37°C for 5 min followed by addition of 3 x 107 unlabeled neutrophils (total vol, 1 ml). One minute later thrombin (5 units/ml), collagen (30 ,tg/ml), or ionophore A23187 (1-2 ,iM) was added. The same protocol was used in HPLC experiments with unlabeled cells. Reactions were stopped at 5 min and lipids were extracted (4). In experiments with unlabeled neutrophils (3 x 107 per ml), 12[3H]HETE (0.45 ,tCi; 9.4 pmol) was added as sodium salt. Thin-Layer Radiochromatography. Lipid extracts were chromatographed on activated (1 hr, 110°C) silica gel G plates (Analtech, Newark, DE) along with standards using chloroform/methanol/acetic acid/water (90:8:1:0.8) (3) as Abbreviations: 12-HETE,12S-hydroxy-5,8-cis,10-trans,14-cis-icosatetraenoic acid; 5-HETE, 5S-hydroxy-6-trans,8,11,14-cis-icosatetraenoic acid; LTB4 (leukotriene B4), 5S,12R-dihydroxy-6-cis,8,10trans,14-cis-icosatetraenoic acid; THETE, trihydroxy-icosatetraenoic acid; ETYA, 5,8,11,14-icosatetraynoic acid; 5S,12S-DiHETE, 5S,12S-dihydroxy-6-trans ,8-cis,10-trans ,14-cis-icosatetraenoic acid; 12,20-DiHETE, (12S)-12,20-dihydroxy-5,8,10,14-icosatetraenoic acid; RP-HPLC, reversed-phase HPLC; SP-HPLC, straightphase HPLC. 903 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 904 Medical Sciences: Marcus et al. solvent. Other TLC-related procedures have been described (5). HPLC Analysis of Icosanoids. In preparation for reversedphase HPLC (RP-HPLC), cell suspensions were extracted as follows: reactions were stopped with 1.5 vol of acetone, precipitated protein was removed by centrifugation, and acetone was evaporated under nitrogen. After acidification to pH 4.0 with 1 M H3PO4, extraction three times with 1 ml aliquots of ethyl acetate, and evaporation to dryness, residues were dissolved in 50 ,l of methanol/water (3:1) and 5 Al was injected into the HPLC column (6). RP-HPLC was carried out on an 8-mm i.d. Radial-PAK C18 (10 ,m) column (Waters) with methanol/water/acetic acid (75:25:0.01) as eluting solvent. Flow rate was 0.7 ml/min. In preparation for mass spectrometry procedures, the product derived from RP-HPLC was esterified using diazomethane and subjected to straight-phase HPLC (SP-HPLC) on a 25-cm Whatman PAC column (10 ,m) using a solvent system of hexane/isopropanol (94:6) with a flow rate of 1.5 ml/min. Under these conditions the new metabolite eluted with a retention time of 14 min. In both HPLC procedures, absorbance was monitored at 237 nm. Preparative Procedures. For larger scale preparations of the new compound, cell ratios were maintained at 3 x 108 platelets per ml to 3 x 107 neutrophils per ml. Total neutrophil numbers ranged from 28 to 67 x 107. The stimulus was thrombin (5 units/ml) and incubations were for 5 or 10 min. Aspirin-treated platelet donors were used to increase yields of 12-HETE and, consequently, the new product. Alternatively, the new metabolite could be prepared from purified 12-HETE added to neutrophils. 12-HETE was synthesized from ionophore-stimulated platelets and purified by HPLC. Catalytic Hydrogenation and Jones Oxidation. After esterification and purification by SP-HPLC, the new metabolite (11.2 ,ug) was dissolved in 1.0 ml of methanol. One milligram of platinum oxide catalyst was added, and hydrogen gas was bubbled through the solution for 10 min at 22°C. The solution was then filtered through Celite under constant N2 pressure to remove the catalyst. The Celite was immediately washed with 30 ml of methanol, and the hydrogenated product was subjected to gas chromatography-mass spectrometry as described (7). A portion of the hydrogenated product (6.8 ,g) was dissolved in 10 ml of acetone and incubated for 20 min at 22°C with 150 Al of Jones reagent (8). The reaction was quenched with 500 Al of isopropanol and the acetone was removed under N2. Ten milliliters of water was added, and the solution was extracted three times with 5 vol of hexane/ethyl acetate (60:40). Finally, the sample was washed twice with equal volumes of water, rotary evaporated to dryness, esterified, and analyzed by gas chromatography-mass spectrometry (7). Sources of all reagents and standards were identical to those previously published (3, 7). RESULTS AND DISCUSSION Thin-Layer Radiochromatographic Studies. Stimulation of cell suspensions containing [3H]arachidonate-labeled platelets and unlabeled neutrophils with thrombin or collagen resulted in production of a labeled compound subsequently identified as (12S)-12,20-dihydroxy-5,8,10,14-icosatetraenoic acid (12,20-DiHETE), which was not synthesized by platelets alone. Thin-layer radiochromatography indicated that this new metabolite had a Rf value intermediate between that of 5S,12S-DiHETE (Rf = 0.41) and 5-HETE (Rf = 0.53) (3). The Rf value observed (0.47) was incompatible with any previously identified neutrophil or platelet icosanoid (Fig. 1). Thrombin or collagen did not initiate arachidonic acid metabolism in neutrophils, as evidenced by lack of production of 5-[3H]HETE or [3H]LTB4 in these experiments. There(3H) ARACHIDONATE-PLATELETS